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302Economic analysis of endovascular repair versus
surveillance for patients with small abdominal
aortic aneurysms
Eric L. Eisenstein, DBA,a Linda Davidson-Ray, MA,a Rex Edwards, BA,a Kevin J. Anstrom, PhD,a
and Kenneth Ouriel, MD,b Durham, NC; and New York, NY
Background: The Positive Impact of EndoVascular Options for Treating Aneurysms Early (PIVOTAL) trial enrolled
individuals with small (4.0- to 5.0-cm diameter) abdominal aortic aneurysms (AAA) and reported no difference in
rupture or aneurysm-related death for patients who received early endovascular repair (EVAR) vs surveillance with serial
imaging studies. We evaluated resource use, medical cost, and quality of life outcomes associated with the PIVOTAL
treatment strategies.
Methods: This prospective economic and quality of life study was conducted within a randomized trial, with PIVOTAL
sites participating in the quality of life (n [ 67) and economic (n [ 63) studies. The PIVOTAL trial randomized 728
patients (366 early EVAR and 362 surveillance). We used information from 701 quality of life (351 early EVAR and 350
surveillance) and 614 economic (314 early EVAR and 300 surveillance) study participants enrolled in the PIVOTAL trial.
The main outcome measures were total medical costs and the aneurysm repair rate at 48 months.
Results: After 6 months, the rate of aneurysm repair was 96 vs 10 per 100 patients in the early EVAR and surveillance
groups, respectively (difference, 86; 95% conﬁdence interval [CI], 82-90; P < .0001), and total medical costs were greater
in the early EVAR group ($33,471 vs $5520; difference, $27,951; 95% CI, $25,156-$30,746; P < .0001). In months 7
through 48, however, the rate of aneurysm repair was 54 per 100 patients in the surveillance group, and total medical
costs were higher for patients in the surveillance vs the early EVAR group ($40,592 vs $15,197; difference, $25,394; 95%
CI, $15,184-$35,605; P < .0001). At 48 months’ follow-up, early EVAR patients had greater cumulative use of AAA
repair (97 vs 64 per 100 patients; difference, 34; 95% CI, 21-46; P < .0001), but there was no difference in total medical
costs ($48,669 vs $46,112; difference, $2557; 95% CI, L$8043 to $13,156; P [ .64). After discounting at 3% per
annum, total medical costs for early EVAR and surveillance patients remained similar ($47,765 vs $43,532; difference,
4232; 95% CI, L$5561 to $14,025; P [ .40). There were no treatment-related differences in quality of life at
24 months.
Conclusions: A treatment strategy involving early repair of smaller AAA with EVAR is associated with no difference in
total medical costs at 48 months vs surveillance with serial imaging studies. Longer follow-up is required to determine
whether the late medical cost increases observed for surveillance will persist beyond 48 months. (J Vasc Surg
2013;58:302-10.)The decision for intervention in abdominal aortic aneu-
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For open surgical repair, a threshold aneurysm diameter of
5.0 to 5.5 cm has been used to gauge risk. However, ques-
tions arise about whether a different threshold for interven-
tion is appropriate for endovascular aneurysm repair
(EVAR).
Two clinical trials evaluated the use of open surgery vs
surveillance in patients with small aneurysms (4.0-5.5 cm).2-4
Both studies, the Aneurysm Detection and Management
(ADAM) and the United Kingdom Small Aneurysm Trial
(UK-SAT), concluded that surveillance conveyed similar
beneﬁts as early open surgery with respect to all-cause
mortality. However, the perioperative risk associated with
EVAR was lower than that with open surgery, and
EVAR clinical event rates varied with aneurysm diam-
eter.5-7 These results have led to speculation that the
AAA diameter threshold for EVAR may be lower than
that for open surgery.8,9
The Positive Impact of EndoVascular Options for
Treating Aneurysms Early (PIVOTAL) study was
a randomized, controlled clinical trial in which early
EVAR was compared with surveillance with serial imaging
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prospectively evaluated long-term economic and quality of
life outcomes associated with an early EVAR vs a surveil-
lance treatment strategy using follow-up information
through 48 months. Our objectives were to compare
differences in medical resource use patterns, medical costs,
and quality of life for EVAR vs surveillance patients by
intention-to-treat.
METHODS
The PIVOTAL protocol was approved by each study
site Institutional Review Board and is registered on
clinicaltrials.gov (NCT00444821). All study patients con-
sented to participate in the PIVOTAL study.
Overview of PIVOTAL trial design and clinical
results. The PIVOTAL clinical trial randomly assigned
728 patients to receive surveillance (n ¼ 362) or early
EVAR (n ¼ 366).10 Patients were included if they were
aged between 40 and 90 years, had infrarenal AAAs 4.0 to
5.0 cm in diameter, as assessed by computed tomography
within 3 months of screening, and did not meet the study’s
exclusion criteria.10 The primary clinical end point was the
composite of rupture or aneurysm-related death. At a mean
follow-up of 20 6 12 months, the mortality rate was 4.1%
in each group (unadjusted hazard ratio [HR] after early
EVAR was 1.01; 95% conﬁdence interval [CI], 0.49-2.07;
P ¼ .98). The rate of aneurysm rupture or aneurysm-
related death was 0.6% in both groups (unadjusted HR,
0.99; 95% CI, 0.14-7.06; P ¼ .99).
Overview of PIVOTAL economic study. We con-
ducted a prospective economic study in PIVOTAL
patients. Our original research plan included two compo-
nents: (1) an intent-to-treat analysis comparing treat-
ment-related differences in resource use, medical costs,
and quality of life outcomes using empiric data collected
during the PIVOTAL follow-up period, and (2) a cost-
effectiveness analysis assessing incremental medical costs
per incremental quality-adjusted life-year for an early
EVAR vs a surveillance treatment strategy. However, the
absence of a mortality and quality of life beneﬁt for early
EVAR limited our analysis to the ﬁrst component.11 The
PIVOTAL Economic Study protocol was approved by
Duke University School of Medicine’s Institutional Review
Board (Protocol ID: Pro00013065). Patients participating
in the economic analysis provided informed consent for
their inpatient bills to be collected by the Duke Economics
and Quality of Life (EQOL) Coordinating Center in
Durham, North Carolina.
Economic data. The study’s economic information
included data elements from the PIVOTAL case report
form (CRF) and information collected by the Duke
EQOL Coordinating Center. CRF information was
collected during scheduled study visits that occurred at
baseline, 6 months, 12 months, and annually thereafter
and included AAA-related ofﬁce visits, imaging studies
(number and type), and EQ-5D (EuroQol Group, Rot-
terdam, The Netherlands) quality of life responses to the
ﬁve dimension questions and a single-question visualanalog scale (VAS) assessment. Site coordinators also
collected patient-reported instances of inpatient care
(emergent, observational stay, acute hospitalization,
nursing home, and rehabilitation facility) and forwarded
this information to the Duke EQOL Coordinating Center.
Duke billing specialists then contacted the ﬁnance depart-
ment at each inpatient care organization, obtained the
appropriate patient bills, and abstracted key information.
Duke personnel also collected Medicare Cost Reports from
each hospital for relevant study years and abstracted their
department-level costs-to-charges ratios.
Different methods were used to estimate the technical
and professional components of each patient’s outpatient
and inpatient medical costs in the PIVOTAL economic
analysis.12 Medical costs for the technical and professional
components of AAA-related ofﬁce visits and imaging
studies were estimated using reimbursements from the
2008 Medicare fee schedule as resource-based proxies for
medical costs. The technical components of inpatient care
were estimated from study patient billing information.
For emergent, observational, and acute care, we multiplied
hospital-speciﬁc departmental charges on study patient bills
by their associated cost-to-charges ratios to derive cost esti-
mates. For rehabilitation facility and nursing home care, we
used per diems. Professional costs for AAA repair (EVAR
and open surgery) were estimated using procedure descrip-
tions from the CRF and Medicare fee schedule amounts.
Professional costs for other inpatient care were estimated
using previously described methods.13,14 All costs were
adjusted to 2008 values using the medical component of
the consumer price index. For reporting of resource use
and medical costs, inpatient care was grouped into the cate-
gories of AAA repair (EVAR device and open surgery) and
other inpatient care, including secondary procedures,
emergency department, other hospitalizations, and rehabil-
itation facility or nursing home.
We used standard methods in the coding of EQ-5D
responses. This instrument has ﬁve dimensions, comprising
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. Each dimension has three levels (no
problems, some problems, and extreme problems). Dimen-
sion responses were collapsed into two levels (problems,
yes or no) in this study’s analyses.15 The EQ-5D utility
score uses responses to the ﬁve dimensions to compute
a value on a scale of 0.54 to 1.00. A higher utility score
indicates a better quality of life and a negative value indi-
cates a health state worse than death that can be used to
quality-adjust study patient survival time.16 The ﬁnal
EQ-5D element, visual analog score (VAS), provides
a one-question assessment of an individual’s quality of life
and ranges from 0-100, with a higher score indicating
a better quality of life.
Statistical analysis. Baseline clinical characteristic and
quality of life results are presented as percentages for
discrete variables and as medians and 25th and 75th
percentiles for continuous variables. Differences between
dichotomous variables are assessed using the c2 statistic
or the Fisher exact test, and differences between
Table I. Baseline characteristics for economic study
patients
Variablesa
Surveillance
(n ¼ 300)
Early EVAR
(n ¼ 314) P
Demographics
Age, years 70.0 (66.0, 76.0) 70.5 (65.0, 77.0) .87
White race 283 (94.3) 289 (92.0) .33
Male sex 251 (83.7) 275 (87.6) .20
AAA diameter, cm 4.40 (4.20, 4.70) 4.50 (4.20, 4.70) .61
Current tobacco use 87 (29.0) 87 (27.7) .77
History of
Family aneurysmal
disease
70 (23.3) 55 (17.5) .09
Coronary artery
disease
169 (56.3) 170 (51.0) .61
Peripheral vascular
disease
79 (26.3) 89 (28.3) .66
Hypertension 222 (74.0) 251 (79.9) .11
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test. Medical resource use, length of stay (LOS), and
medical costs are presented as cumulative values by treat-
ment with differences, 95% CIs, and P values. These values
are presented within time periods of interest (0-6 months,
7-48 months, and cumulative). Analyses are performed for
the entire population, for the prospectively deﬁned
subgroups of initial AAA diameter 4.0 to 4.5 cm and 4.6 to
5.0 cm, and for the investigative subgroups of patients with
and without a history of coronary artery disease (CAD).
Resource use, LOS, and medical cost analyses are per-
formed on partitioned data using general linear models
with inverse probability weighted adjustment for censoring
and empiric standard errors.17,18 Total medical cost anal-
yses were performed with and without discounting at 3%
per annum.19 Statistical analyses were performed using SAS
8.2 or higher software (SAS Institute, Cary, NC).Abdominal surgery 116 (38.7) 120 (38.2) .95
Gastrointestinal
disease
110 (36.7) 119 (37.9) .84
AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair.
aCategoric variables are presented as number (%) and continuous variables as
median (25th, 75th).RESULTS
Study population and baseline characteristics. The
PIVOTAL clinical trial enrolled 728 patients (366 early
EVAR and 362 surveillance).10 Sites participating in the
PIVOTAL quality of life study enrolled 710 patients, and
sites participating in the economic study enrolled 666
patients. For the quality of life analyses, we eliminated
patients who did not complete the EQ-5D instrument at
time intervals of interest (baseline, 12 months, and
24 months). For the PIVOTAL economic analysis, we
excluded 52 patients (27 early EVAR and 25 surveillance)
who were enrolled at per diem hospitals that did not
generate detailed patient bills, yielding 614 patients (314
early EVAR and 300 surveillance). The initial AAA diam-
eter subgroup analysis was limited to 607 patients (310
early EVAR and 297 surveillance) because AAA diameter
was not available for seven patients. Similarly, the CAD
history subgroup analysis was limited to 611 patients (313
early EVAR and 298 surveillance) because CAD history
was missing for three patients. Average follow-up time was
similar for treatment groups (938 days for early EVAR and
934 days for surveillance).
Baseline characteristics. Economic study patients
randomized to early EVAR and surveillance were well
matched and similar to those in the PIVOTAL clinical trial
(Table I).10 Most patients were older white men with
a history of hypertension and CAD.
Medical resource use. There were signiﬁcant
treatment-related differences in the use of EVAR and
total repair at 0 to 6 months, 7 to 48 months, and overall
(Table II). More early EVAR patients received AAA repair
during the initial 6 months; whereas, more surveillance
patients received AAA repair between 7 and 48 months. At
the end of follow-up, almost all patients randomized to
early EVAR and >60% randomized to surveillance had
received AAA repair. There were no treatment-related
differences in other types of inpatient care, and early
differences in AAA visits and imaging studies reported at
6 months’ follow-up did not persist.Length of stay. Treatment-related differences in AAA
repair LOS paralleled differences in the use of AAA repair
procedures (Table III). Early EVAR patients had greater
AAA repair LOS during months 0 to 6; whereas, surveil-
lance patients had greater AAA repair LOS during the
remaining study period. Although other hospitalizations
and rehabilitation facility or nursing home care accounted
for most LOS days for patients in both study arms (92%
surveillance and 82% early EVAR), there was no treatment-
related difference for this combined LOS category
(surveillance, 1665.3 days/100 patients; early EVAR,
917.5; difference, 747.8; 95% CI, 583.0 to 2078.6;
P ¼ .27).
Medical costs. Treatment-related differences in
medical costs were driven by differences in AAA procedure
use and LOS (Table IV). Early EVAR patients had greater
AAA repair costs during the initial 6 months and during the
0 to 48 months of follow-up; whereas, surveillance patients
had greater AAA repair costs during months 7 to 48.
Medical costs associated with other hospitalizations and
rehabilitation facility and nursing home care for surveil-
lance patients were nearly as large as those for AAA repair
procedures, whereas those for early EVAR patients were
much smaller. Nonetheless, there was no treatment-related
difference for this combined medical cost category
(surveillance, $20,507; early EVAR, $14,634; difference,
$5873; 95% CI, $2715 to $14,462; P ¼ .18). Overall,
there were no treatment-related differences in total medical
costs at 48 months.
Discounting served to amplify treatment-related cumu-
lative cost differences (Table V). However, these differ-
ences were not signiﬁcant overall or for patients with
smaller (4.0-4.5 cm) and larger (4.6-5.0 cm) diameter
aneurysms.
Table II. Medical resource use per 100 patientsa
Resource type Surveillance (n ¼ 300) Early EVAR (n ¼ 314) Difference (95% CI) P
0-6 months
AAA repair
Endograft device 9.7 94.9 85.2 (89.3 to 81.0) <.0001
Open surgery 0.3 1.3 0.9 (2.4 to 0.5) .19
Total repair 10.0 96.2 86.1 (90.2 to 82.0) <.0001
Other inpatient care
Secondary procedures 0.7 1.3 0.6 (2.2 to 0.9) .44
Emergency department 1.7 2.9 1.2 (3.6 to 1.2) .32
Other hospitalizationsb 14.0 19.5 5.5 (13.8 to 2.9) .20
Rehab facility/nursing home 1.0 1.9 0.9 (3.3 to 1.5) .46
Outpatient care
AAA visits 54.8 110.2 55.4 (63.2 to 47.6) <.0001
Imaging studies 53.5 92.7 39.2 (45.5 to 32.8) <.0001
7-48 months
AAA repair
Endograft device 52.3 0.8 51.6 (39.2 to 64.0) <.0001
Open surgery 1.4 0.4 1.0 (0.8 to 2.8) .29
Total repair 53.7 1.2 52.6 (40.1 to 65.0) <.0001
Other inpatient care
Secondary procedures 1.6 2.0 0.4 (3.3 to 2.5) .79
Emergency department 8.7 16.6 7.9 (21.5 to 5.7) .25
Other hospitalizationsb 124.7 92.1 32.6 (18.4 to 83.6) .21
Rehab facility/nursing home 20.1 7.0 13.0 (17.8 to 43.8) .41
Outpatient care
AAA visits 635.6 595.3 40.3 (5.1 to 85.6) .08
Imaging studies 320.8 308.7 12.1 (15.8 to 40.0) .39
Total
AAA repair
Endograft device 62.0 95.6 33.6 (46.2 to 21.1) <.0001
Open surgery 1.7 1.7 0.0 (2.2 to 2.3) .98
Total repair 63.8 97.4 33.6 (46.0 to 21.1) <.0001
Other inpatient care
Secondary procedures 2.3 3.3 1.0 (4.3 to 2.3) .55
Emergency department 10.4 19.5 9.1 (22.9 to 4.7) .20
Other hospitalizations b 138.7 111.6 27.1 (24.9 to 79.2) .31
Rehab facility/nursing home 21.1 9.0 12.1 (18.8 to 43.0) .44
Outpatient care
AAA visits 690.4 705.5 15.1 (60.7 to 30.5) .52
Imaging studies 374.4 401.4 27.0 (55.7 to 1.6) .07
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; EVAR, endovascular aneurysm repair.
aCell values are rates per 100 patients.
bIncludes non-AAA-related hospitalizations.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 2 Eisenstein et al 305Quality of life. PIVOTAL patients reported prob-
lems with pain/discomfort and mobility and, to a lesser
extent, with performing usual activities and anxiety/
depression (Table VI). However, there were no
treatment-related differences in the ﬁve EQ-5D quality of
life dimensions or the utility score at baseline or at the
12-month and 24-month follow-up. Early EVAR vs
surveillance patients reported lower VAS scores at
12 months; however, their scores were similar at baseline
and at 24 months.
History of CAD. Although not statistically signiﬁcant,
medical costs for other hospitalizations were higher in
surveillance vs early EVAR patients and other hospitaliza-
tions with a primary diagnosis of diseases of the circulatory
system (International Classiﬁcation of Diseases-9th edition,
390-459) accounted for $2349 (49%) of the $4773
treatment-related difference in other hospitalizationmedical costs. Patients with a history of CAD represented
55% of all study patients, 54% of those with smaller-
diameter aneurysms (4.0-4.5 cm), and 58% with larger-
diameter aneurysms (4.6-5.0 cm). Although there were
no treatment-related differences in baseline characteristics,
patients with vs without a history of CAD had greater
history of peripheral vascular disease, hypertension, and
gastrointestinal disease, with no differences in age or initial
AAA diameter (Table VII). AAA repair-related medical
costs appear to be driven by the rates of AAA repair in both
patient groups. However, there also appears to be an
interaction between CAD history and other hospitaliza-
tions (Table VIII). In patients with a history of CAD,
medical costs for other hospitalizations and cardiovascular
hospitalizations are signiﬁcantly higher for surveillance vs
early EVAR patients. Results for patients without a history
of CAD show no treatment-related differences in other
Table III. Average length of stay per 100 patientsa
Resource type Surveillance (n ¼ 300) Early EVAR (n ¼ 314) Difference (95% CI) P
0-6 months
Total AAA repairb 18.1 166.1 138.9 (158.3 to 119.5) <.0001
Secondary procedures 1.3 4.5 3.1 (8.7 to 2.5) .27
Emergency department 2.7 3.5 0.8 (4.5 to 2.8) .65
Other hospitalizationsc 56.2 117.3 61.1 (130.3 to 8.0) .08
Rehab facility/nursing home 26.8 69.9 43.0 (169.9 to 83.9) .51
Total 105.0 361.2 256.2 (420.5 to 91.8) .02
7-48 months
Total AAA repairb 92.8 4.1 83.8 (54.6 to 113.0) <.0001
Secondary procedures 8.1 2.9 5.2 (8.6 to 18.9) .46
Emergency department 9.9 16.6 6.8 (20.7 to 7.2) .34
Other hospitalizationsc 580.9 407.7 173.2 (104.5 to 450.9) .22
Rehab facility/nursing home 1001.5 322.7 678.8 (529.4 to 1887.0) .27
Total 1693.1 754.0 939.0 (357.7 to 2235.8) .16
Total
Total AAA repairb 110.8 170.2 55.1 (89.6 to 20.5) .02
Secondary procedures 9.4 7.4 2.0 (12.8 to 16.8) .79
Emergency department 12.6 20.1 7.6 (22.0 to 6.8) .30
Other hospitalizationsc 637.0 525.0 112.0 (177.3 to 401.4) .45
Rehab facility/nursing home 1028.3 392.5 635.8 (590.3 to 1861.8) .31
Total other inpatient care 1798.1 1115.3 682.8 (650.3 to 2015.9) .32
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; EVAR, endovascular aneurysm repair.
aCell values are days per 100 patients.
bThe sum of EVAR and open surgery.
cIncludes non-AAA-related hospitalizations.
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costs; however, there is a signiﬁcant difference in total
medical costs at 48 months that largely is driven by higher
AAA repair-related medical costs in early EVAR vs
surveillance patients.
DISCUSSION
The PIVOTAL research program provides the ﬁrst
randomized trial with the combination of clinical,
economic, and quality of life components evaluating the
use of an early EVAR strategy vs surveillance with serial
imaging studies treatment strategy for patients with small
AAAs. At the 48-month follow-up, there were no
treatment-related differences in total medical costs, and at
24 months, there were no treatment-related differences
in quality of life (EQ-5D ﬁve dimensions, utility score,
and VAS). During the ﬁrst 6 months, the use of early
EVAR was associated with higher medical costs than
surveillance; however, this trend was reversed in follow-
up months 7 to 48. These results are driven by
treatment-related differences in the rate and timing of
AAA repair procedures.
Given the high variability inherent in medical costs
data, results for the subgroups of patients with smaller-
diameter (4.0-4.5 cm) and larger-diameter (4.6-5.0 cm)
AAAs were remarkably consistent with the overall medical
cost results. This was true for total medical costs at
48 months and for important cost drivers. AAA-related
medical costs accounted for 46% of total medical costs
for surveillance and 61% for early EVAR in all study
patients. Similar cost distributions were observed for
patients with smaller and larger aneurysms.Results for surveillance patients with and without
a history of CAD were quite different. Both groups had
similar age, AAA diameter, and history of family aneurysm
disease, but surveillance patients with vs without a history
of CAD had greater history of cardiovascular disease
(peripheral vascular disease and hypertension) and gastro-
intestinal disease. These differences were associated with
higher rates of AAA repair, other hospitalizations, and
cardiovascular hospitalizations. These differences in
resource use led to higher AAA repair-related, other hospi-
talization, cardiovascular hospitalization, and total medical
costs for patients with vs without a history of CAD and
suggest that disease progression may be different for these
two patient groups. Although there was no signiﬁcant
treatment-related difference in total medical costs for
patients with a history of CAD, these results suggest that
the economics of AAA repair may be quite different for
different patient groups.
Few studies have investigated quality of life and medical
cost differences for an early intervention (EVAR or open
surgery) vs a surveillance treatment strategy in patients
with small AAAs. The Comparison of surveillance vs Aortic
Endografting for Small Aneurysm Repair (CAESAR) trial
reported higher Medical Outcomes Study Short Form-36
scores (total, mental domain, and physical domain) for
early EVAR vs surveillance at 6 months.20 However,
these differences rapidly diminished, such that there were
no signiﬁcant differences after 12 months. Although
PIVOTAL used a different instrument (EQ-5D), our
results at 12 and 24 months of follow-up also failed to
demonstrate consistent treatment-related differences in
quality of life.
Table IV. Average medical costs per patienta
Cost type Surveillance (n ¼ 300) Early EVAR (n ¼ 314) Difference (95% CI) P
0-6 months
Inpatient
Total AAA repairb 3095 29,491 26,397 (28,365 to 24,428) <.0001
Secondary procedures 73 236 163 (467 to 141) .29
Emergency department 48 31 17 (41 to 74) .57
Other hospitalizationsc 1710 2642 933 (2590 to 724) .27
Rehab facility/nursing home 285 178 107 (333 to 547) .63
Outpatient
AAA visits 12 25 12 (14 to 11) <.0001
Imaging studies 297 868 570 (629 to 512) <.0001
Total medical costs 5520 33,471 27,951 (30,746 to 25,156) <.0001
7-48 months
Inpatient
Total AAA repairb 18,189 351 17,838 (13,411 to 22,265) <.0001
Secondary procedures 428 306 121 (555 to 797) .73
Emergency department 177 147 30 (171 to 232) .77
Other hospitalizationsc 16,353 10,648 5706 (1570 to 12,981) .12
Rehab facility/nursing home 2159 1166 994 (1505 to 3492) .44
Outpatient
AAA visits 141 132 9 (1 to 19) .08
Imaging studies 3144 2447 696 (357 to 1036) <.0001
Total medical costs 40,592 15,197 25,394 (15,184 to 35,605) <.0001
Total
Inpatient
Total AAA repairb 21,284 29,842 8558 (13,224 to 3893) .0003
Secondary procedures 501 542 41 (780 to 698) .91
Emergency department 226 178 47 (162 to 257) .66
Other hospitalizationsc 18,063 13,290 4773 (2702 to 12,247) .21
Rehab facility/nursing home 2445 1344 1101 (1454 to 3655) .40
Outpatient
AAA visits 154 157 3 (14 to 7) .52
Imaging studies 3441 3315 126 (222 to 474) .48
Total medical costs 46,112 48,669 2557 (13,156 to 8043) .64
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; EVAR, endovascular aneurysm repair.
aMedical costs are presented as dollars per patient.
bSum of EVAR and open surgery.
cIncludes non-AAA-related hospitalizations.
Table V. Average medical costs by initial aneurysm diameter per patienta
Variables
Ultrasound surveillance
(n ¼ 300)
Early EVAR
(n ¼ 314) Difference (95% CI) P
All patients
Undiscounted 46,112 48,669 2557 (13,156 to 8043) .63
Discounted 43,532 47,765 4232 (14,025 to 5561) .40
AAA 4.00-4.50 cm (n ¼ 191) (n ¼ 197)
Undiscounted 48,017 47,229 788 (16,943 to 18,520) .93
Discounted 45,121 46,457 1336 (17,502 to 14,831) .87
AAA 4.51-5.00 cm (n ¼ 106) (n ¼ 113)
Undiscounted 46,733 51,008 4276 (20,294 to 11,742) .60
Discounted 44,295 49,918 5623 (20,576 to 9330) .46
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; EVAR, endovascular aneurysm repair.
aMedical costs are presented as dollars per patient. Discount rate is 3% per annum.
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Small Aneurysm Trial (UK-SAT). Because this study re-
ported no survival advantage for open surgery, the
UK-SAT investigators conducted a cost-minimization study
to examine treatment-related differences in medical costs
and quality of life at the 12-month follow-up.4 Medical costsfor the early surgery group were 25% higher than those for
surveillance. However, early surgery patients reported better
outcomes for current health perceptions and less negative
change in bodily pain. Although this was a well-conducted
study, limiting follow-up to 12 months meant that only
34% of surveillance patients had undergone aneurysm repair.
Table VI. EQ-5D quality of life per patienta
Variables
Ultrasound
surveillance, No.
Early EVAR,
No. P
Respondents
Baseline 350 351
12 months 308 318
24 months 197 205
No. (%) No. (%)
Mobility problems
Baseline 151 (43.1) 130 (37.0) .099
12 months 114 (37.0) 119 (37.4) .915
24 months 73 (37.1) 80 (39.0) .684
Self-care problems
Baseline 16 (4.6) 11 (3.1) .322
12 months 20 (6.5) 17 (5.3) .542
24 months 13 (6.6) 16 (7.8) .640
Usual activity
problems
Baseline 114 (32.6) 101 (28.8) .275
12 months 93 (30.2) 114 (35.8) .132
24 months 57 (28.9) 78 (38.0) .053
Pain/discomfort
Baseline 191 (54.6) 183 (52.1) .518
12 months 144 (46.8) 154 (48.4) .674
24 months 80 (40.6) 94 (45.9) .288
Anxious/
depressed
Baseline 86 (24.6) 94 (26.8) .503
12 months 82 (26.6) 82 (25.8) .811
24 months 36 (18.3) 41 (20.0) .660
Mean 6 SD (n) Mean 6 SD (n)
Utility score
Baseline 0.783 6 0.2 (349) 0.805 6 0.1 (348) .397
12 months 0.794 6 0.2 (299) 0.799 6 0.2 (311) .713
24 months 0.817 6 0.2 (191) 0.797 6 0.2 (203) .391
Visual analog scale
Baseline 78.2 6 15 (350) 77.8 6 14 (351) .382
12 months 78.1 6 16 (308) 75.4 6 17 (318) .030
24 months 76.5 6 18 (197) 76.2 6 17 (205) .669
EVAR, Endovascular aneurysm repair; SD, standard deviation.
aCell values per patient are presented.
Table VII. Baseline characteristics by history of coronary
artery disease (CAD)
Variablea
Ultrasound
surveillance Early EVAR P
History of CAD (n ¼ 169) (n ¼ 170)
Demographics
Age, years 70.0 (66.0, 75.0) 71.0 (65.0, 76.0) .77
White race 162 (95.9) 164 (96.5) .77
Male sex 151 (89.4) 152 (89.4) .99
AAA diameter 4.40 (4.20, 4.70) 4.50 (4.20, 4.70) .31
Current
tobacco use
40 (23.7) 42 (24.7) .82
History of
Family history
of AA
41 (24.3) 30 (17.7) .14
Peripheral
vascular
disease
41 (24.3) 63 (37.1) .18
Hypertension 139 (82.3) 145 (85.3) .45
Abdominal
surgery
71 (42.0) 68 (40.0) .71
Gastrointestinal
disease
70 (41.4) 71 (41.8) .95
No history of CAD (n ¼ 129) (n ¼ 143)
Demographics
Age, years 71.0 (67.0, 76.0) 70.0 (65.0, 77.0) .48
White race 119 (92.3) 124 (86.7) .14
Male sex 98 (76.0) 122 (85.3) .053
AAA diameter 4.40 (4.20, 4.70) 4.45 (4.20, 4.70) .69
Current
tobacco use
47 (36.4) 45 (31.5) .39
History of
Family history
of AA
29 (22.5) 25 (17.5) .30
Peripheral
vascular
disease
28 (21.7) 26 (18.2) .47
Hypertension 83 (64.3) 106 (74.1) .08
Abdominal
surgery
45 (34.9) 52 (36.4) .80
Gastrointestinal
disease
40 (31.0) 48 (33.6) .65
AA, Aortic aneurysm; AAA, abdominal aortic aneurysm; EVAR, endovas-
cular aneurysm repair.
aCategoric clinical variables are presented as number (%) and continuous
variables as median (25th, 75th).
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merhorn et al21 used a Markov model to investigate the
potential economic attractiveness of open surgery in patients
with lower operative mortality deﬁned by younger age and
larger AAA diameter. This study assumed 61% of surveil-
lance patients eventually underwent open surgery and
assigned a utility weight of 0.86 for both treatment groups.
A small quality-adjusted survival advantage was reported for
early open surgery at a small incremental cost. However,
whether the model included all cost types is unclear.
Young et al22 used a Markov model to evaluate the
cost-effectiveness of early EVAR for small AAA vs elective
repair (EVAR or open surgery). Results from this model
predicted that the use of early EVAR vs surveillance was
associated with fewer quality-adjusted life-years and greater
medical costs. This assessment was based on a 0.05 reduc-
tion in quality-adjusted life-years and an increased cost of
$3000 (2007 US$) with early EVAR. This model assumedutility weights of 0.75 for surveillance, 0.70 for EVAR in
the ﬁrst year, and 0.71 for EVAR in the second year.
Medical costs for a number of events are included in this
model, but the list is not exhaustive.
Our study methods differed from these previous efforts
in several ways that had important implications for our
ﬁndings. First, we prospectively collected patient-level
medical cost data at the episode-of-care level. Although
outpatient care typically follows patterns that are captured
relatively well in Medicare reimbursements, this is not the
case with inpatient care that varies in the volume, type,
and price of resources that are used for similar cases.
Thus, studies not capturing this level of detail may under-
estimate the true variability inherent in their study results.
Second, we collected data for all inpatient care, and did
not limit this work to certain types of cases. Models are able
Table VIII. Economic outcomes at 48 months by history of coronary artery disease (CAD)
Variable
Ultrasound
surveillance Early EVAR Difference (95% CI) P
History of CAD (n ¼ 169) (n ¼ 170)
Resource usea
AAA repairb 71.3 97.6 26.3 (44.8 to 7.9) .005
Other hospitalizationsc 180.8 119.2 61.6 (23.3 to 146.5) .16
Other cardiovascular 34.4 17.1 17.3 (1.3 to 35.8) .069
Medical costs,d $
AAA repairb 23,239 29,351 6112 (12,876 to 651) .076
Other hospitalizationsc 22,062 10,822 11,240 (860 to 21,619) .034
Other cardiovascular 4761 2128 3222 (85 to 6360) .044
Total 52,336 45,343 6994 (8352 to 22,339) .37
No history of CAD (n ¼ 129) (n ¼ 143)
Resource usea
AAA repairb 55.2 96.9 41.7 (57.7 to 25.7) <.0001
Other hospitalizations c 88.8 110.1 21.3 (70.4 to 27.7) .39
Other cardiovascular 12.0 27.6 15.6 (32.4 to 1.2) .069
Medical costs,d $
AAA repair b 19,188 30,325 11,137 (17,438 to 4837) .0005
Other hospitalizationsc 13,200 16,679 3479 (13,911 to 6954) .51
Other cardiovascular 2196 4675 2479 (5843 to 886) .15
Total 38,921 52,890 13,969 (27,920 to 18) .050
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; EVAR, endovascular aneurysm repair.
aPresented as rates per 100 patients.
bThe sum of EVAR and open surgery.
cIncludes non-AAA-related hospitalizations.
dPresented as dollars per patient.
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able to inform decision making when key relationships
are not known in advance. Collecting data on all-cause
inpatient care is an important consideration because it can
be difﬁcult to distinguish disease-related from none
disease-related resource use.
Third, the combination of above factors allowed us to
represent results with conﬁdence limits, not as point esti-
mates. This is important because medical costs typically
have extreme variability.
Fourth, we collected quality of life results over a sufﬁ-
cient period of time to determine that early treatment-
related differences did not persist.
Our study has important limitations. First, PIVOTAL
was not designed to investigate possible interactions
between treatment and baseline clinical characteristics.
Thus, although our analyses of patients with vs without
a history of CAD are interesting, they are not deﬁnitive
and will need to be replicated in future studies. Second,
our study results are limited to the population of patients
enrolled in the PIVOTAL clinical trial. We believe that
our results accurately reﬂect the long-term resource use,
medical costs, and quality of life outcomes for this popula-
tion, but they may not be transferrable to other popula-
tions of patients with small AAAs.
CONCLUSIONS
A treatment strategy involving early repair of smaller
AAA with EVAR is associated with no difference in total
medical costs at 48 months and no difference in qualityof life at 24 months vs surveillance with serial imaging
studies. Longer follow-up is required to determine whether
the late medical cost increases observed for surveillance will
persist beyond 48 months.
We thank Allyn Meredith, MA, for her expert editorial
assistance.
AUTHOR CONTRIBUTIONS
Conception and design: EE, LD, KO
Analysis and interpretation: EE, RE, KA, KO
Data collection: EE, LD
Writing the article: EE
Critical revision of the article: EE, LD, RE, KA, KO
Final approval of the article: EE, LD, RE, KA, KO
Statistical analysis: EE, RE, KA
Obtained funding: EE
Overall responsibility: EE
REFERENCES
1. Ouriel K. Randomized clinical trials of endovascular repair versus
surveillance for treatment of small abdominal aortic aneurysms.
J Endovasc Ther 2009;16(suppl 1):I94-105.
2. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN,
Acher CW, et al. Immediate repair compared with surveillance of small
abdominal aortic aneurysms. N Engl J Med 2002;346:1437-44.
3. Mortality results for randomised controlled trial of early elective surgery
or ultrasonographic surveillance for small abdominal aortic aneurysms.
The UK Small Aneurysm Trial Participants. Lancet 1998;352:1649-55.
4. Health service costs and quality of life for early elective surgery or
ultrasonographic surveillance for small abdominal aortic aneurysms.
UK Small Aneurysm Trial Participants. Lancet 1998;352:1656-60.
JOURNAL OF VASCULAR SURGERY
310 Eisenstein et al August 20135. Ouriel K, Srivastava SD, Sarac TP, O’Hara PJ, Lyden SP,
Greenberg RK, et al. Disparate outcome after endovascular treatment
of small versus large abdominal aortic aneurysm. J Vasc Surg 2003;37:
1206-12.
6. Peppelenbosch N, Buth J, Harris PL, van Marrewijk C, Fransen G.
Diameter of abdominal aortic aneurysm and outcome of endovascular
aneurysm repair: does size matter? A report from EUROSTAR. J Vasc
Surg 2004;39:288-97.
7. Zarins CK, Crabtree T, Bloch DA, Arko FR, Ouriel K, White RA.
Endovascular aneurysm repair at 5 years: does aneurysm diameter
predict outcome? J Vasc Surg 2006;44:920-9; discussion: 929-31.
8. Zarins CK, White RA, Moll FL, Crabtree T, Bloch DA, Hodgson KJ,
et al. The Aneurx stent graft: four-year results and worldwide experi-
ence 2000. J Vasc Surg 2001;33:S135-45.
9. Zarins CK. The US Aneurx clinical trial: 6-year clinical update 2002.
J Vasc Surg 2003;37:904-8.
10. Ouriel K, Clair DG, Kent KC, Zarins CK. Endovascular repair
compared with surveillance for patients with small abdominal aortic
aneurysms. J Vasc Surg 2010;51:1081-7.
11. Mark DB, Hlatky MA. Medical economics and the assessment of value
in cardiovascular medicine: part II. Circulation 2002;106:626-30.
12. Eisenstein EL. Conducting an economic analysis to assess the elec-
trocardiogram’s value. J Electrocardiol 2006;39:241-7.
13. Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA,
et al. Long-term clinical and economic analysis of the Endeavor drug-
eluting stent versus the Driver bare-metal stent: 4-year results from the
ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the
Safety and Efﬁcacy of the Medtronic AVE ABT-578 Eluting Driver
Coronary Stent in De Novo Native Coronary Artery Lesions). JACC
Cardiovasc Interv 2009;2:1178-87.14. Mitchel J, Burge R, Lee A. Per case prospective payment for episodes of
hospital care. Document number: PB95226023. Springﬁeld, VA:
Presented to U.S. Department of Commerce National Technical
Information Service; 1995.
15. Brooks R, Rabin R, de Charro F. The measurement and valuation of
health status using EQ-5D: a European perspective: evidence from the
EuroQol Biomed Research Program. Boston, MA: Kluwer Academic
Publishers; 2003.
16. Dolan P. Modeling valuations for EuroQol health states. Med Care
1997;35:1095-108.
17. Bang H, Tsiatis AA. Estimating medical costs with censored data.
Biometrika 2000;87:329-43.
18. Ziegler SL, Liang KY. Longitudinal data analysis for discrete and
continuous outcomes. Biometrics 1986;42:121-30.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in
health and medicine. New York: Oxford University Press; 1996.
20. De Rango P, Verzini F, Parlani G, Cieri E, Romano L, Loschi D, et al.
Quality of life in patients with small abdominal aortic aneurysm: the
effect of early endovascular repair versus surveillance in the CAESAR
trial. Eur J Vasc Endovasc Surg 2011;41:324-31.
21. Schermerhorn ML, Birkmeyer JD, Gould DA, Cronenwett JL. Cost-
effectiveness of surgery for small abdominal aortic aneurysms on the
basis of data from the United Kingdom Small Aneurysm Trial. J Vasc
Surg 2000;31:217-26.
22. Young KC, Awad NA, Johansson M, Gillespie D, Singh MJ, Illig KA.
Cost-effectiveness of abdominal aortic aneurysm repair based on
aneurysm size. J Vasc Surg 2010;51:27-32; discussion: 32.Submitted Jul 11, 2012; accepted Jan 27, 2013.
